NASDAQ · DRUG
Bright Minds Biosciences Inc.
$56.69+$1.37 (+2.48%)
Bright Minds Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.19% below the high.
Loading market information…
CNQ · BNXT.CN · CAD
Stock price, earnings
Quote as of Oct 29, 2026, 02:07 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CAD. Historical prices are not a forecast.
BioNxt Solutions Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.86% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow BioNxt Solutions Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Headquartered in Vancouver, Canada, BioNxt Solutions Inc., established in 2017, operates as a bioscience company across Germany, Switzerland, Austria, Israel, and its home country. The firm focuses on developing innovative drug delivery systems, including transdermal patches and oral dissolvable films, specifically for neurological medications. It also advances psychedelic medicine applications to treat various mental health conditions such as depression, anxiety, addiction, and trauma-related stress disorder. Furthermore, BioNxt is engaged in creating point-of-care diagnostics, comprising rapid tests and biosensor screening tools, aimed at early disease detection, improved treatment efficacy, and enhanced disease management. This diagnostic portfolio features a COVID-19 PCR kit, alongside oral biosensors for peri-implantitis, H1N1 (swine flu), and H5N1 (avian flu). Complementing its development efforts, the company provides analytical testing and consulting services, and is involved in pathogen and oral health diagnostics, thin film drug formulation, and the production and formulation of psychedelic pharmaceuticals. The company adopted its current name in November 2022, having previously been known as XPhyto Therapeutics Corp.
Latest available per-share figures in CAD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$56.69+$1.37 (+2.48%)
Bright Minds Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.19% below the high.
CA$15.01-CA$0.21 (-1.38%)
Cybin Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.42% below the high.
CA$0.25+CA$0.01 (+4.17%)
BetterLife Pharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 45.65% below the high.
CA$0.16CA$0.00 (0.0%)
Pharmala Biotech Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.52% below the high.
CA$0.11+CA$0.01 (+10.0%)
Rapid Dose Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 42.11% below the high.
CA$0.02CA$0.00 (0.0%)
PreveCeutical Medical Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
CA$0.04-CA$0.02 (-27.27%)
Lobe Sciences Ltd.’s quoted price sits in the lower half of its reported 52-week range, 77.78% below the high.
CA$1.90CA$0.00 (0.0%)
InnoCan Pharma Corporation’s quoted price sits in the lower half of its reported 52-week range, 90.08% below the high.
